Image: AI-generated editorial illustration
Hone Health announced $228 million in new financing on November 18, combining a $28 million Series A extension led by MarcyPen Capital Partners with $200 million from General Catalyst’s Customer Value Fund.
Hone Health announced $228 million in new financing on November 18, combining a $28 million equity round led by MarcyPen Capital Partners with $200 million from General Catalyst’s Customer Value Fund. Fortune reported that the equity portion was structured as a Series A extension rather than a Series B, and that the larger financing is designed to support growth rather than function as traditional equity.
The company is positioning the money behind both expansion and product development. According to reported company plans, Hone wants to push deeper into longevity-focused care through its Longevity OS platform, diagnostics, metabolic care, PCOS-related care, peptides and clinical trials. Athletech News reported that the financing is also meant to support Hone’s physician-led longevity care and research platform, including its AI-powered technology.
Who led the equity round?
MarcyPen Capital Partners led the $28 million equity financing, with participation from Kinship Ventures and other backers including Pentland Ventures, Hanwha, Gannet Capital and Humbition. Fortune reported that MarcyPen also said it had led Hone’s earlier Series A, a role that had not previously been public.
MarcyPen was formed in 2024 through the merger of Jay-Z’s Marcy Venture Partners and Pendulum Holdings’ investment arm. Fortune also reported that individual investors include the Jonas Brothers, Kelly Rowland, Marcello Hernández, David Grutman, Jason Strauss, Noah Tepperberg and Quentin Dolan. Gwyneth Paltrow said she is also a Hone patient.
What is General Catalyst’s Customer Value Fund?
General Catalyst’s $200 million commitment comes through its Customer Value Fund, a structure Fortune described as paying for a large share of a company’s sales and marketing and being repaid from the revenue new customers generate. In other words, it is not the same as a straight equity investment, and it does not create equivalent dilution for existing shareholders.
Hone CEO Saad Alam said the deal has no recourse and no covenants restricting the company from raising other capital. He also said General Catalyst only offers the structure to companies whose patients stay at a steady rate. Fortune reported that the Customer Value Fund financing is intended to support growth, including sales and marketing.
What does Hone say it will do with the money?
Most of the $28 million equity round will go to AI, according to Alam, with the goal of helping one physician handle issues that would otherwise send a patient to several specialists. Athletech News reported that Hone plans to invest in its proprietary AI platform, Longevity OS, which combines patient health data, lab results and treatment history to help physicians personalize care plans.
The company also appears to be broadening its clinical footprint. Athletech News reported that Hone will expand into metabolic health, inflammation and immune health, and add diagnostics such as full-body MRI, DEXA scans and coronary CT angiography. Other stated priorities include physician-supervised peptide therapies and clinical research. Tech Funding News also said the company’s expansion plans include Longevity OS, diagnostics, metabolic care, PCOS-related care, peptides and clinical trials.
Hone is additionally publicly launching Hone Black, a concierge longevity membership that had operated privately for the past year. Athletech News reported that Hone Black combines testing across more than 1,600 health markers with ongoing care from a dedicated physician team, and that treatment options include prescription medications, supplements, peptides and other therapies.
How has Hone grown since launch?
Hone began in 2020 as an online clinic treating men with low testosterone. Fortune said the company has since treated about 200,000 patients since launch, up from 55,000 patients reported in January 2025. Alam also said Hone broke through $100 million in recurring revenue last year.
Athletech News reported that the company later expanded into weight management, cardiovascular health and menopause treatment, and that it has administered over 750,000 tests, citing the company’s latest figures. Tech Funding News said Hone has about 450 staff, including doctors, and operates only in the U.S., attributing that information to Alam.
Alam also said Hone is the first business under a parent company called Time Therapeutics. Looking ahead, Fortune reported that his plan is to build a large online clinic, use the patient base to run clinical trials remotely, and then partner with drugmakers and research centers to bring drugs to market faster in exchange for equity.
Sources
- Jay-Z's MarcyPen and Gwyneth Paltrow's Kinship back Hone Health in $228m raisetechfundingnews.com· Tech Funding News
- Hone Health raises $228.0M Series A led by MarcyPen Capital Partnersmidu.si· Midu
- Hone Health lands $228 million with backing from Jay-Z’s firm and Gwyneth Paltrow. She’s an investor—and a patientfortune.com· Fortune
- Hone Health Gets $228M to Expand Longevity Platformathletechnews.com· Athletech News



